Quant Biomarkers established to develop sophisticated analytical products
Quant Biomarkers - 10-Dec-2021DKG subsidiary to introduce biomarker-driven Longevity risk mitigation and intervention support
The Live Forever Club is evolving. Subscribe to the newsletter to be the first to hear about this important change.
CEO Quant Biomarkers and Managing Partner Deep Knowledge Group
More than a decade of work as strategic development head for several large Swiss and international pharmaceutical corporations (Novartis, Abbott Life Sciences).
Dr. Tomovska has a vast amount of experience across pharmaceutical portfolio stages and business delivery: strategy, lifecycle, venture development, R&D, M&A, clinical, marketing, and change management. She holds a PhD in molecular biology from the University of Basel, Switzerland in Biomarkers in Cancer Diagnostics and has a business education from INSEAD and Columbia Business School.
Visit website: https://www.quant-biomarkers.com/#team
See alsoDetails last updated 14-Dec-2021
DKG subsidiary to introduce biomarker-driven Longevity risk mitigation and intervention support